ABSTRACT Prostaglandin D 2 (PGD 2 ) causes cough and levels are increased in asthma suggesting that it may contribute to symptoms. Although the prostaglandin D 2 receptor 2 (DP 2 ) is a target for numerous drug discovery programmes little is known about the actions of PGD 2 on sensory nerves and cough.
Introduction
Prostaglandin D 2 (PGD 2 ) is a major cyclooxygenase product produced by mast cells, with lower levels produced by other cells such as T-helper (Th)2 cells, alveolar macrophages, dendritic cells and platelets [1] [2] [3] [4] . Increased levels of PGD 2 have been found in asthmatics [5, 6] and following allergen challenge in patients with asthma [7, 8] . PGD 2 has many effects in the airways that may contribute to asthma pathophysiology including increased mucus production [9] , vasodilation [10] and capillary permeability [11] . Inhalation of PGD 2 induces bronchoconstriction in normal volunteers and this is more profound in patients with asthma [12, 13] . More recently PGD 2 has been demonstrated to possess chemoattractive properties for eosinophils, basophils and Th2 lymphocytes [14] . PGD 2 is generated by metabolism of arachidonic acid through the cyclooxygenase pathway and then by PGD synthase enzymes. PGD 2 elicits its biological activity through pharmacologically distinct G protein-coupled receptors (GPCR). Initially most of its effects were attributed to activation of the prostaglandin D 2 receptor (DP 1 ) and at high concentrations activity at the thromboxane (TP) receptors. However, more recently PGD 2 was identified as the cognate ligand for an orphan GPCR (GPR44), which had been identified on inflammatory cells. This receptor was originally named CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells), but is now known as the DP 2 receptor in line with prostanoid receptor nomenclature [15] . In recent years significant research effort has been directed into the pro-inflammatory effects of PGD 2 and evidence suggests that PGD 2 , via the DP 2 receptor, recruits inflammatory cells to the airways [14] . In line with these observations there are now several DP 2 antagonists being trialled for the treatment of asthma and allergic diseases [16] . PGD 2 has been shown to cause cough in preclinical studies and in clinical studies following nasal challenge [17, 18] . Furthermore, increased levels of PGD 2 are found in the airways of asthmatics [5, 7] and chronic coughers [19] , and it is recognised that sensory nerve associated symptoms like excessive coughing are part of the asthma phenotype. However, nothing is known about the activity of PGD 2 on airway sensory nerves. We have shown for the first time that PGD 2 causes dose-related cough in guinea pigs and activates single C-fibre airway afferents in vivo via DP 1 receptor activation. This finding is supported with pharmacological data in human, guinea pig and gene-deficient mouse vagal tissues confirming a role for the DP 1 receptor and suggesting that antagonists at this receptor may be useful for the treatment of symptoms such as cough in patients with asthma. Having found that both DP 1 and DP 2 are expressed in guinea pig vagal ganglia we further investigated DP receptor modulation of vagal nerve activity. Interestingly, we discovered that activation of the DP 2 receptor actually inhibits vagal nerve activity. Therefore, in conditions where endogenous PGD 2 levels are elevated, loss of DP 2 receptor-mediated inhibition of sensory nerves may lead to an increase in vagally associated symptoms such as cough and should be investigated in clinical studies with novel DP 2 antagonists.
Methods
Animals Male C57BL/6 and BALB/c mice (18-20 g ) and Dunkin Hartley guinea pigs (250-350 g) were purchased from Harlan (Bicester, UK). Breeding pairs of mice devoid of one of the following genes Ptgdr (DP 1 ), Gpr44 (DP 2 ), Tbxa2r (TP), Trpa1 and Trpv1 had been backcrossed at least eight times onto their respective backgrounds (DP 1 , TP, TRPA1 and TRPV1 on a C57BL/6 background; DP 2 on a BALB/c background). Experiments were performed under UK Home Office project licence (PPL 70/7212) and procedures strictly adhered to the Animals (Scientific Procedures) Act 1986.
Cough and bronchospasm in vivo
Guinea pigs were placed in a plethysmography chamber and vehicle or PGD 2 delivered by aerosol via a nebuliser for 10 min. Cough was measured as previously described [20] [21] [22] .
Assessing calcium movement in airway jugular ganglia cells Guinea pig, airway specific, jugular neurons were labelled, extracted and dissociated as described previously [21] and in the online supplementary material. For calcium imaging the cells were loaded with 6 μM Fura-2 acetoxymethyl ester (Fura-2 AM). Viability of the cells was assessed by applying 50 mM potassium solution at the start and finish of experiments. PGD 2 (1 μM) or capsaicin (0.1 μM) was applied for 70 s. For inhibition experiments, the inhibitor was applied for 10 min and the agonist re-applied in the presence of inhibitor. After a wash period, the agonist was reapplied. Intracellular calcium change was recorded and analysed using Image J (US National Institutes of Health, Bethesda, MD, USA, http://imagej. nih.gov/ij/).
Gene expression in vagal nerve ganglia
Guinea pig jugular ganglia were dissected as described in the previous section and the supplementary material. RNA was extracted and samples reverse-transcribed [23] . Primers and probes for the guinea pig DP 1 and DP 2 receptors were designed and produced by Applied Biosystems (Life Technologies Ltd, Paisley, UK). Data are expressed as 2 -Δct ×10 6 where Δct represents the difference in the expression of the target compared with 18S rRNA.
Recording from single C-fibre afferents in vivo Guinea pigs were anaesthetised with urethane (1.5 g·kg
) intraperitoneally with neuromuscular blockade using vecuronium bromide (0.10 mg·kg −1 intravenous, followed every 20 min with 0.05 mg·kg −1 i.v.). The trachea was cannulated and lungs ventilated. Both vagus nerves were cut and the left vagus nerve was used for recording. The vagus nerve was teased until a single active unit was obtained and action potentials were recorded as previously described [24] . After a control baseline recording of 2 min, capsaicin (100 μM) was administered by aerosol for 15 s and the changes in fibre activity, intratracheal pressure and blood pressure recorded. Agonists were aerosolised for 60 s at 10-min intervals while recording variables. Verification of a C-fibre was confirmed at the end of the experiment by determining conduction velocity. All animals were subsequently killed with an overdose of pentobarbitone.
In vitro vagus nerve preparation Guinea pig, mouse and human vagus nerves were dissected, placed in Krebs-Henseleit solution and mounted in a "grease-gap" recording chamber as previously described (further details can be found in the online supplementary material) [21] . Agonists were applied for 2 min followed by Krebs-Henseleit solution. For antagonist experiments, two reproducible responses to agonists were acquired. The antagonist or vehicle was perfused for 10 min and immediately afterwards the agonist was reapplied for 2 min in the presence of the antagonist and the degree of inhibition recorded. Concentrations of antagonists were selected as 100-fold of the pA2 value (a measure of antagonist affinity).
Compounds and materials PGD 2 , prostaglandin E2 (PGE 2 ), 15(R)-15-methyl-PGD 2 , BW245C, BWA868C, CAY10471, SQ29548 were purchased from Cayman Europe (Tallinn, Estonia). Capsaicin and JNJ17203212 were purchased from Sigma-Aldrich (Poole UK). HC-030031 was purchased from Chembridge (San Diego, CA, USA). All salts were from BDH (VWR International Ltd, Poole, UK) and Sigma-Aldrich. Details on preparation of solutions can be found in the online supplementary material.
Data analysis and statistics
Data are presented as mean±SEM and statistical significance was denoted as p<0.05. Paired t-test, MannWhitney U-test, Kruskal-Wallis test and repeated measures ANOVA were used as appropriate to the dataset and calculated using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
PGD 2 -induced cough PGD 2 causes cough and bronchospasm in man [12] . PGD 2 caused a dose-dependent increase in the number of coughs ( fig. 1 ). Having established that we could parallel the effect of PGD 2 pre-clinically, we then employed a range of in vivo and in vitro systems, selective ligands and gene-deficient mice to investigate the receptors involved.
Effect of PGD 2 in airway jugular ganglia cells PGD 2 can activate primary airway specific jugular ganglia (i.e. as assessed by an increase in intracellular calcium) ( fig. 2a-c) . Furthermore quantitative real-time PCR analysis showed that both the DP 1 and DP 2 receptors are present in whole guinea pig jugular ganglia ( fig. 2d) . However, the expression data were performed on whole ganglia and the results should be interpreted with caution given vagal ganglia also contain microvasculature, glial cells and Schwann cells as well as neurons that project all over the viscera. Therefore, the source of the mRNA may not be neuronal.
In vivo single afferent fibre recording in guinea pig Inhaled capsaicin, a TRPV1 agonist, was used to identify a single airway C-fibre [24] (fig. 3a) . C-fibres were characterised by their responsiveness to aerosolised capsaicin and their conduction velocities. The C-fibres used in this study had mean±SEM conduction velocities of 0.72±0.07 m·s −1 (range: 0.6-0.85 m·s
−1
). The DP 1 receptor agonist (BW245C) and PGD 2 caused a burst of firing, whereas the DP 2 receptor agonist (15(R)-15-methyl-PGD 2 ) had no effect ( fig. 3b and c) . Interestingly, PGD 2 and the DP 2 receptor agonist (but not the DP 1 receptor agonist) induced a bronchoconstriction ( fig. 3d ). Using isolated guinea pig tracheal smooth muscle we confirmed that the PGD 2 -induced contraction was mediated by the TP receptor ( fig. S1 ). In this system, the DP 1 receptor agonist had no effect on tone whereas the DP 2 receptor agonist caused contraction, which was inhibited by the TP (and not the DP 2 ) receptor antagonist (fig. S1b and c).
Preliminary data also suggested that PGD 2 and the DP 1 agonist can evoke action potential discharge in mechanoreceptors (mid-range, capsaicin-sensitive Aδ fibre conduction velocity (CV) 4.9 m·s ). At least for the DP 1 agonist this is not accompanied by bronchospasm and in both cases this is restricted to capsaicin-sensitive fibres, which suggests that this happens via direct activation of capsaicin-sensitive fibres and via the DP 1 receptor/TRPV1-TRPA1 axis. PGD 2 -induced guinea pig and mouse isolated vagal nerve depolarisation Many tussive agents [25, 26] , such as capsaicin, low pH solutions and PGE 2 , are known vagal sensory nerve stimulants and isolated guinea pig, murine and human vagus nerve preparations have been shown to elicit similar nerve depolarisation responses across the species to these stimulants [20] [21] [22] . These data suggest that the isolated vagus nerve is a useful and predictive preparation for conducting comprehensive pharmacological assessments of agents that may activate or inhibit sensory nerve function and, thus, the cough reflex that is not complicated by the pharmacokinetics and other considerations which limit the interpretation of in vivo studies. Using this system, we showed that PGD 2 causes a concentration related increase in depolarisation in guinea pig isolated vagal nerves ( fig. 4a) . In guinea pig isolated vagus nerves, BWA868C (DP 1 receptor antagonist) inhibited PGD 2 -induced depolarisation in a concentration dependent manner ( fig. 4b ), but not PGE 2 (a similar PG known to excite sensory nerve driven responses 22) (data not shown). Furthermore, CAY10471 (DP 2 receptor antagonist) and SQ29548 (TP receptor antagonist) had no effect on the response to PGD 2 ( fig. 4b ). In addition, BW245C (DP 1 receptor agonist) caused depolarisation in guinea pig vagal nerves, but 15(R)-15-methyl-PGD 2 (DP 2 receptor agonist) had no effect ( fig. 4d ). Utilising vagal tissue from gene-deficient mice to corroborate these findings we found that the response to PGD 2 (10 μM) is virtually abolished in vagal tissue from the Ptgdr −/− (DP 1 receptor deficient) mice, compared with wild type (C57BL/6 and BALB/c), Gpr44 −/− (DP 2 receptor deficient) and Tbxa2r
(TP receptor deficient) mice ( fig. 4c) . 
DP 1 receptor mediated depolarisation induced by PGD 2 in human vagal tissue
The DP 1 receptor antagonist BWA868C significantly inhibited PGD 2 -induced depolarisation ( fig. 5a and b) and the DP 1 , but not the DP 2 receptor agonist, caused depolarisation of human vagus ( fig. 5c ). An example trace of the inhibitory effects of BWA868C can be seen in figure 5b.
Signalling pathway involved in DP 1 receptor-mediated nerve activation The DP 1 receptor is a GPCR and it is likely that following ligand binding it regulates ion channels involved in the post-receptor signalling pathway to evoke depolarisation. TRPV1 and TRPA1 are ion channels known to be expressed on sensory nerves and activation of these is known to evoke cough in guinea pig conscious cough models and in man [20, 26] . The depolarisation to PGD 2 in guinea pig isolated vagal nerves was partially inhibited by TRPV1 (JNJ17203212) and TRPA1 (HC030031) antagonists at concentrations previously shown to maximally inhibit TRPV1 and TRPA1 agonists, respectively ( fig. 6a) [21] . Furthermore, the responses in isolated nerves from Trpv1 −/− and Trpa1 −/− mice were significantly reduced compared with wild type (fig. 6b ). This suggests a role for both TRPV1 and TRPA1 in the depolarisation induced by PGD 2 .
The role of the DP 2 receptor in the modulation of vagal nerve activation The data presented so far provides strong evidence that PGD 2 activates airway sensory nerves via the DP 1 and not the DP 2 receptor. However, both receptors are expressed on the vagal jugular ganglia. Although the DP 2 receptor does not activate vagal nerves it is still possible that the receptor may modulate sensory nerve activity. Using guinea pig isolated vagal nerves and airway specific jugular ganglia cells we discovered that the DP 2 receptor agonist inhibited responses to the sensory C-fibre stimulant capsaicin ( fig. 7a and b) . This effect translates to man as the DP 2 agonist also inhibited capsaicin-induced depolarisation in human isolated vagus nerve ( fig. 7c) . Furthermore, using guinea pig isolated vagus nerves, we have shown that the inhibitory effect on the capsaicin signal is blocked by a DP 2 receptor antagonist ( fig. 7d) . Finally, we have illustrated the inhibitory effect of the DP 2 receptor in vivo as the DP 2 receptor agonist significantly reduced capsaicin-induced C-fibre single afferent firing ( fig. 8) . 
Discussion
PGD 2 is released from mast cells, Th2 cells and dendritic cells [1] [2] [3] [4] , it is increased in the airways of patients with asthma [5, 6] and there is strong evidence to suggest that it may be involved in the allergic inflammatory response that characterises asthma and allergic rhinitis. In support of this contention are data demonstrating that mice deficient in the DP 1 receptor do not develop an asthmatic phenotype in an ovalbumin-induced asthma model [27] . Furthermore, in a guinea pig model of allergic airway inflammation, a selective DP 1 receptor antagonist, S-5751, reduced antigen-induced nasal blockage, plasma exudation in the conjunctiva, and inflammatory cell infiltration into the upper and lower airways [28] . The prostaglandin D receptor gene (PTGDR) has also been implicated in the asthma phenotype as a result of linkage and association analyses in human subjects [29] and reports that specific variants in the PTGDR promoter are associated with asthma [30] . PGD 2 is also thought to contribute to symptoms such as excessive cough [17, 18] . Asthma and nonasthmatic eosinophilic bronchitis are among the most common causes of chronic cough. Interestingly, mast cell mediators such as histamine and PGD 2 are increased in sputum in nonasthmatic eosinophilic bronchitis, suggesting that activation of mast cells is a particular feature of this condition and that mast cell mediators may be responsible for the cough [31] . However, our understanding of the mechanisms involved in PGD 2 -induced cough is limited. PGD 2 activates DP 1 , DP 2 and TP receptors, but it is not known which receptor and post-receptor signalling pathways are involved in the activation of airway sensory nerves and the cough reflex. In order to investigate this further we wanted to identify an appropriate preclinical model system. We decided to use the guinea pig as this species is commonly used to investigate airway sensory nerve biology and guinea pigs cough in a similar fashion to humans in response to a range of tussive agents [20, 21, 26] . PGD 2 evoked cough in conscious guinea pigs. This was shown to be an effect on airway specific afferents evidenced by the observation that PGD 2 evoked calcium influx into airway specific jugular cells. Furthermore, PGD 2 and a selective DP 1 receptor agonist, but not a DP 2 receptor agonist, caused C-fibre firing in an in vivo electrophysiological model [32] . Using a range of pharmacological tools and vagal tissue from receptor deficient mice (although mice do not cough their vagal afferent responses are in many cases similar and comparable to guinea pigs and humans) we have provided significant evidence to suggest that the PGD 2 -induced sensory nerve activation is mediated by the DP 1 (and not DP 2 or TP) receptor. The TP receptor was investigated alongside DP 1 and DP 2, even though TP receptor agonists are not thought to cause cough [33] , because PGD 2 is known to mediate airway smooth muscle contraction through the TP receptor [32, 34] , a finding that was confirmed in this study. One possibility that cannot be ruled out is that PGD 2 -induced bronchoconstriction (via TP activation) could cause cough indirectly via activation of mechanosensitive RARs. However, selective activation of the DP 1 receptor can evoke action potential firing independent of bronchospasm favouring the theory that it is direct activation of airway afferents that causes PGD 2 -induced cough. Clinically relevant data was also presented confirming the findings above and demonstrating, for the first time, a role for DP 1 receptor activation by PGD 2 in human vagal tissue.
The DP 1 receptor is generally thought to be coupled to the G-protein G s , suggesting that activation of the DP 1 receptor would cause an increase in cAMP [35, 36] . However, this is in contrast to our previous research in similar biological systems, which suggests that elevation of cAMP has an inhibitory effect on airway sensory nerve activation [37] . Interestingly, and more consistent with the data shown here, cells expressing DP 1 receptors have also been shown to elicit an increase in intracellular calcium when stimulated by PGD 2 or the selective DP 1 agonist BW245C [35] . This increase in intracellular calcium appears to be cAMP-dependent and may result from the activation of protein kinase A (PKA) and subsequent involvement of L-type Ca 2+ channels and the ryanodine receptor [38] . The mechanisms downstream of GPCR coupling that lead to activation of ion channels are not yet fully understood, but phospholipase C (PLC) and PKA pathways are thought to be important in the signalling for a number of TRP channels [39] [40] [41] . GPCR binding to G q -coupled receptors can lead to activation of PLC, hydrolysis of phosphatidylinositol-(4,5)-bisphosphate (PIP 2 ) to yield inositol-(1,4,5)-trisphosphate (IP 3 ), production of diacylglycerol (DAG) and activation of protein kinase C (PKC). PKC and DAG have been found to directly bind the TRPV1 receptor, and IP 3 -induced release of intracellular calcium stores may be involved in activation of TRPA1. Moreover, PIP 2 is thought to constitutively inhibit TRP receptors. Therefore, its hydrolysis by PLC may disinhibit these ion channels, sensitising them to subsequent stimulation [41] . Alternatively, PKA-dependent phosphorylation can occur through activation of G s -coupled receptors, thereby enhancing ion channel excitability [41] . The TRPV1 and TRPA1 ion channels are known to be expressed on airway sensory nerves and agonists at these receptors cause cough [20, 21, 25] . In this study, we have shown that both TRPV1 and TRPA1 mediate the downstream response to PGD 2 following DP 1 receptor activation. Both the TRPV1 and TRPA1 antagonists partially inhibited the depolarisation response to PGD 2 . Furthermore, in vagal tissue from Trpv1 −/− and Trpa1 −/− mice the response to PGD 2 was significantly reduced. These channels have also been implicated in cough induced by PGE 2 acting via the prostaglandin E receptor 3 [22] .
Throughout the body, the DP 1 receptor is either undetectable or expressed at low levels in tissues [35, 36] , whereas the DP 2 receptor is widely distributed [42] . In guinea pig vagal ganglia we have detected both DP 1 and DP 2 mRNA. However, whole vagal ganglia also contain other cell types including Schwann cells, glial cells and microvasculature as well as neurons that project into the viscera and so identification of DP receptors in these samples does not provide conclusive evidence. Therefore, in this study we have elucidated a function for the DP 1 receptor in activating airway sensory nerves and eliciting reflex events such as cough. However, a selective DP 2 receptor agonist did not cause depolarisation and a DP 2 antagonist did not inhibit the response to PGD 2 . In addition to causing depolarisation agents have also been shown to sensitise nerves to the effects of other stimuli [43, 44] or inhibit nerve activation [37] . We investigated this further and found that a DP 2 receptor agonist inhibited capsaicin-induced activation of airway jugular ganglia cells, and isolated vagal nerves from both guinea pig and human, and that this effect was blocked by a DP 2 receptor antagonist. Furthermore, this was confirmed in the in vivo single fibre recording model in which capsaicin-induced action potential firing was reduced following the administration by an aerosol of a DP 2 receptor agonist. In fact, the modest cough responses evoked by PGD 2 in this study and the interesting observation that DP 2 receptor activation may inhibit C-fibre discharge may suggest that a DP 2 receptor antagonist could enhance the cough responses evoked by PGD 2 . Since the discovery that DP 2 receptor antagonists could inhibit allergen-induced inflammation there has been a major focus for drug discovery in the asthma area over recent years and there are several compounds in clinical trials [16] . However, this data would suggest that caution should be exercised when developing DP 2 antagonists for asthma as preventing DP 2 receptor activation (especially when endogenous PGD 2 production is high as is possible in allergic diseases) may be detrimental and result in inappropriate stimulation of airway reflexes.
In conclusion, there is strong evidence to suggest that mast cell mediators such as PGD 2 may be involved in the symptoms associated with the allergic inflammatory response that characterises asthma and allergic rhinitis. There is also evidence suggesting that this involves, at least in part, DP 1 receptor activation. However, in spite of the encouraging data from asthma genetic association studies, preclinical studies using pharmacological interventions and DP 1 receptor knockout mice in asthma models, DP 1 receptor antagonists have been disappointing in clinical studies and are not currently used therapeutically. In particular, the DP 1 antagonist laropiprant had no efficacy in patients with allergic rhinitis and asthma where forced expiratory volume in 1 s was the primary end-point [45] . The evidence we present here demonstrates PGD 2 activates airway sensory nerves to evoke cough and provides clear evidence for the involvement of DP 1 receptors in airway reflex events. This data suggests that this target should be revisited in clinical trials specifically configured to look at symptoms, utilising new clinical tools such as objective cough measurement [46, 47] .
